Post-Treatment Follow-Up and Management of Latent Tuberculosis Infection (LTBI)

Monitoring and Management

The European Respiratory Society and American Thoracic Society recommend that patients require routine monthly clinical monitoring during LTBI therapy to assess adherence, review symptoms of adverse drug reactions, and check for signs of hepatotoxicity 1, 2
The American Thoracic Society recommends that patients should be educated to immediately stop treatment and contact their provider if they develop symptoms such as unexplained anorexia, nausea, vomiting, dark urine, jaundice, persistent paresthesias, persistent fatigue, abdominal tenderness, easy bruising/bleeding, or rash 1, 2
The Centers for Disease Control and Prevention (CDC) guidelines state that routine laboratory monitoring is NOT indicated for all patients, but baseline and periodic liver function tests are required for high-risk patients, including those with HIV infection, history of liver disease, or regular alcohol use 1, 2, 3

The European Respiratory Society recommends that once LTBI treatment is successfully completed, no further routine clinical monitoring or testing is necessary, unless there is new exposure or development of symptoms suggestive of active disease 1, 2
The CDC guidelines state that patients who complete treatment do not need repeat tuberculin skin tests or IGRA tests unless new exposure occurs 4

The European Respiratory Society recommends that close clinical observation for at least 2 years is preferred over preventive treatment for contacts of multidrug-resistant TB patients 1
The CDC guidelines state that HIV-infected patients and those on immunosuppressive therapy should maintain heightened awareness for TB symptoms even after completing LTBI treatment 5

The American Thoracic Society recommends that if treatment is interrupted, the reason should be assessed, and treatment may be considered adequate if the patient completed ≥80% of planned doses 2, 4

The CDC guidelines state that patients who previously completed a full LTBI treatment course should not be retreated unless there is documented new exposure with high likelihood of reinfection 4, 3

Patients in high-risk groups, such as healthcare workers, correctional facility staff, and homeless shelter workers, may require repeat chest X-ray due to ongoing exposure risk 6
The European Respiratory Society is not cited for this fact, however, annual screening for LTBI is recommended for HIV-infected patients and those on immunosuppressive therapy if ongoing risk factors for TB exposure exist 6
Patients on biologics or immunosuppressive medications who had a positive TST or IGRA at baseline often remain positive even after successful LTBI treatment, and require monitoring for clinical signs and symptoms of recurrent TB disease 6
Chest radiography may be considered in patients with risk factors when clinically indicated, even with negative repeat TST or IGRA 6